<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33987813</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>03</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-7479</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>3</Issue><PubDate><Year>2021</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics</Title><ISOAbbreviation>Neurotherapeutics</ISOAbbreviation></Journal><ArticleTitle>Drug Repurposing: A Network-based Approach to Amyotrophic Lateral Sclerosis.</ArticleTitle><Pagination><StartPage>1678</StartPage><EndPage>1691</EndPage><MedlinePgn>1678-1691</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s13311-021-01064-z</ELocationID><Abstract><AbstractText>The continuous adherence to the conventional "one target, one drug" paradigm has failed so far to provide effective therapeutic solutions for heterogeneous and multifactorial diseases as amyotrophic lateral sclerosis (ALS), a rare progressive and chronic, debilitating neurological disease for which no cure is available. The present study is aimed at finding innovative solutions and paradigms for therapy in ALS pathogenesis, by exploiting new insights from Network Medicine and drug repurposing strategies. To identify new drug-ALS disease associations, we exploited SAveRUNNER, a recently developed network-based algorithm for drug repurposing, which quantifies the proximity of disease-associated genes to drug targets in the human interactome. We prioritized 403 SAveRUNNER-predicted drugs according to decreasing values of network similarity with ALS. Among catecholamine, dopamine, serotonin, histamine, and GABA receptor modulators, as well as angiotensin-converting enzymes, cyclooxygenase isozymes, and serotonin transporter inhibitors, we found some interesting no customary ALS drugs, including amoxapine, clomipramine, mianserin, and modafinil. Furthermore, we strengthened the SAveRUNNER predictions by a gene set enrichment analysis that confirmed modafinil as a drug with the highest score among the 121 identified drugs with a score &gt;&#x2009;0. Our results contribute to gathering further proofs of innovative solutions for therapy in ALS pathogenesis.</AbstractText><CopyrightInformation>&#xa9; 2021. The American Society for Experimental NeuroTherapeutics, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fiscon</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-3354-8203</Identifier><AffiliationInfo><Affiliation>Institute for Systems Analysis and Computer Science "A. Ruberti", National Research Council (IASI-CNR), Via Dei Taurini 19, 00185, Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fondazione per la Medicina Personalizzata, Via Goffredo Mameli, Genova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Conte</LastName><ForeName>Federica</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-0427-1476</Identifier><AffiliationInfo><Affiliation>Institute for Systems Analysis and Computer Science "A. Ruberti", National Research Council (IASI-CNR), Via Dei Taurini 19, 00185, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amadio</LastName><ForeName>Susanna</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-9266-4597</Identifier><AffiliationInfo><Affiliation>IRCCS Santa Lucia Foundation, Preclinical Neuroscience, Via Del Fosso di Fiorano 65, 00143, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Volont&#xe9;</LastName><ForeName>Cinzia</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-7362-8307</Identifier><AffiliationInfo><Affiliation>Institute for Systems Analysis and Computer Science "A. Ruberti", National Research Council (IASI-CNR), Via Dei Taurini 19, 00185, Rome, Italy. cinzia.volonte@cnr.it.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IRCCS Santa Lucia Foundation, Preclinical Neuroscience, Via Del Fosso di Fiorano 65, 00143, Rome, Italy. cinzia.volonte@cnr.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paci</LastName><ForeName>Paola</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-9393-2047</Identifier><AffiliationInfo><Affiliation>Institute for Systems Analysis and Computer Science "A. Ruberti", National Research Council (IASI-CNR), Via Dei Taurini 19, 00185, Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Computer, Control, and Management Engineering Antonio Ruberti (DIAG), Sapienza University, Rome, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>05</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurotherapeutics</MedlineTA><NlmUniqueID>101290381</NlmUniqueID><ISSNLinking>1878-7479</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000697">Central Nervous System Stimulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="Y">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000697" MajorTopicYN="N">Central Nervous System Stimulants</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058492" MajorTopicYN="N">Drug Repositioning</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053263" MajorTopicYN="N">Gene Regulatory Networks</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054730" MajorTopicYN="N">Protein Interaction Domains and Motifs</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Drug repositioning</Keyword><Keyword MajorTopicYN="N">Histaminergic drugs</Keyword><Keyword MajorTopicYN="N">Modafinil</Keyword><Keyword MajorTopicYN="N">Network Medicine</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>4</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>14</Day><Hour>7</Hour><Minute>11</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33987813</ArticleId><ArticleId IdType="pmc">PMC8609089</ArticleId><ArticleId IdType="doi">10.1007/s13311-021-01064-z</ArticleId><ArticleId IdType="pii">10.1007/s13311-021-01064-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Masrori P, Damme PV. Amyotrophic lateral sclerosis: a clinical review. Eur J Neurol 2020; 0: 1&#x2013;12.</Citation></Reference><Reference><Citation>Oskarsson B, Gendron TF, Staff NP. Amyotrophic lateral sclerosis: an update for 2018. Mayo Clin Proc. 2018;93:1617&#x2013;1628.</Citation><ArticleIdList><ArticleId IdType="pubmed">30401437</ArticleId></ArticleIdList></Reference><Reference><Citation>Gromicho M, Figueiral M, Uysal H, et al. Spreading in ALS: The relative impact of upper and lower motor neuron involvement. Ann Clin Transl Neurol. 2020;7:1181&#x2013;1192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7359118</ArticleId><ArticleId IdType="pubmed">32558369</ArticleId></ArticleIdList></Reference><Reference><Citation>Burk K, Pasterkamp RJ. Disrupted neuronal trafficking in amyotrophic lateral sclerosis. Acta Neuropathol (Berl) 2019;137:859&#x2013;877.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6531423</ArticleId><ArticleId IdType="pubmed">30721407</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravits J, Paul CJP. Focality of upper and lower motor neuron degeneration at the clinical onset of ALS. Neurology 2007; 68: 1571&#x2013;1575.</Citation><ArticleIdList><ArticleId IdType="pubmed">17485643</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappello V, Francolini M. Neuromuscular Junction Dismantling in Amyotrophic Lateral Sclerosis. Int J Mol Sci 2017; 18 (10):&#xa0;2092.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5666774</ArticleId><ArticleId IdType="pubmed">28972545</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Luo JZ, Jianxun Yi, Changling Ma, et al. Defective Mitochondrial Dynamics Is an Early Event in Skeletal Muscle of an Amyotrophic Lateral Sclerosis Mouse Model. PLoS ONE 2013; 8: e82112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3855744</ArticleId><ArticleId IdType="pubmed">24324755</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Appel SH. Immune dysregulation in amyotrophic lateral sclerosis: mechanisms and emerging therapies. Lancet Neurol. 2019;18:211&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pubmed">30663610</ArticleId></ArticleIdList></Reference><Reference><Citation>Verber N, Shaw PJ. Biomarkers in amyotrophic lateral sclerosis: a review of new developments. Curr Opin Neurol. 2020;33:662&#x2013;668.</Citation><ArticleIdList><ArticleId IdType="pubmed">32796280</ArticleId></ArticleIdList></Reference><Reference><Citation>Wobst HJ, Mack KL, Brown DG, et al. The clinical trial landscape in amyotrophic lateral sclerosis&#x2014;Past, present, and future. Med Res Rev. 2020;40:1352&#x2013;1384.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7417284</ArticleId><ArticleId IdType="pubmed">32043626</ArticleId></ArticleIdList></Reference><Reference><Citation>Pushpakom S, Iorio F, Eyers PA, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019;18:41&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">30310233</ArticleId></ArticleIdList></Reference><Reference><Citation>Kukharsky MS, Skvortsova VI, Bachurin SO, et al. In a search for efficient treatment for amyotrophic lateral sclerosis: Old drugs for new approaches. Med Res Rev. Epub ahead of print 20 August 2020. 10.1002/med.21725.</Citation></Reference><Reference><Citation>Caldera M, Buphamalai P, M&#xfc;ller F, et al. Interactome-based approaches to human disease. Curr Opin Syst Biol. 2017;3:88&#x2013;94.</Citation></Reference><Reference><Citation>Barab&#xe1;si A-L, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat Rev Genet. 2011;12:56&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3140052</ArticleId><ArticleId IdType="pubmed">21164525</ArticleId></ArticleIdList></Reference><Reference><Citation>Barab&#xe1;si A-L. Network Medicine &#x2014; From Obesity to the &#x201c;Diseasome&#x201d;. N Engl J Med. 2007;357:404&#x2013;407.</Citation><ArticleIdList><ArticleId IdType="pubmed">17652657</ArticleId></ArticleIdList></Reference><Reference><Citation>Silverman EK, Schmidt H, Anastasiadou E, et al. Molecular networks in Network Medicine: Development and applications. WIREs Syst Biol Med. 2020;12:e1489.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7955589</ArticleId><ArticleId IdType="pubmed">32307915</ArticleId></ArticleIdList></Reference><Reference><Citation>Paci P, Fiscon G, Conte F, et al. Gene co-expression in the interactome: moving from correlation toward causation via an integrated approach to disease module discovery. Npj Syst Biol Appl. 2021;7:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7819998</ArticleId><ArticleId IdType="pubmed">33479222</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonawane AR, Weiss ST, Glass K, et al. Network Medicine in the Age of Biomedical Big Data. Front Genet 2019; 10: 294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6470635</ArticleId><ArticleId IdType="pubmed">31031797</ArticleId></ArticleIdList></Reference><Reference><Citation>Goh K-I, Cusick ME, Valle D, et al. The human disease network. Proc Natl Acad Sci. 2007;104:8685&#x2013;8690.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1885563</ArticleId><ArticleId IdType="pubmed">17502601</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Hou Y, Shen J, et al. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discov. 2020;6:1&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7073332</ArticleId><ArticleId IdType="pubmed">32194980</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng F, Desai RJ, Handy DE, et al. Network-based approach to prediction and population-based validation of in silico drug repurposing. Nat Commun. 2018;9:2691.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6043492</ArticleId><ArticleId IdType="pubmed">30002366</ArticleId></ArticleIdList></Reference><Reference><Citation>Morselli GD, do Valle &#xcd;, Zitnik M, Ameli A, Gan X, Varol O, Ghiassian SD, Patten JJ, Davey RA, Loscalzo J, Barab&#xe1;si AL. Network medicine framework for identifying drug-repurposing opportunities for COVID-19. Proc Natl Acad Sci U S A 2021; 118(19):e2025581118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8126852</ArticleId><ArticleId IdType="pubmed">33906951</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiscon G, Conte F, Farina L, et al. SAveRUNNER: A network-based algorithm for drug repurposing and its application to COVID-19. PLOS Comput Biol. 2021;17:e1008686.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7891752</ArticleId><ArticleId IdType="pubmed">33544720</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiscon G, Paci P. SAveRUNNER: an R-based tool for drug repurposing. BMC Bioinformatics. 2021;22:150.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7987121</ArticleId><ArticleId IdType="pubmed">33757425</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatr-Aryamontri A, Breitkreutz BJ, Oughtred R, et al. The BioGRID interaction database: 2015 update. Nucleic Acids Res. 2015;43:D470&#x2013;478.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4383984</ArticleId><ArticleId IdType="pubmed">25428363</ArticleId></ArticleIdList></Reference><Reference><Citation>Peri S, Navarro JD, Kristiansen TZ, et al. Human protein reference database as a discovery resource for proteomics. Nucleic Acids Res. 2004;32:D497&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC308804</ArticleId><ArticleId IdType="pubmed">14681466</ArticleId></ArticleIdList></Reference><Reference><Citation>Licata L, Briganti L, Peluso D, et al. MINT, the molecular interaction database: 2012 update. Nucleic Acids Res. 2012;40:D857&#x2013;861.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3244991</ArticleId><ArticleId IdType="pubmed">22096227</ArticleId></ArticleIdList></Reference><Reference><Citation>Orchard S, Ammari M, Aranda B, et al. The MIntAct project&#x2013;IntAct as a common curation platform for 11 molecular interaction databases. Nucleic Acids Res. 2014;42:D358&#x2013;363.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3965093</ArticleId><ArticleId IdType="pubmed">24234451</ArticleId></ArticleIdList></Reference><Reference><Citation>Breuer K, Foroushani AK, Laird MR, et al. InnateDB: systems biology of innate immunity and beyond&#x2013;recent updates and continuing curation. Nucleic Acids Res. 2013;41:D1228&#x2013;1233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3531080</ArticleId><ArticleId IdType="pubmed">23180781</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu W, Clyne M, Khoury MJ, et al. Phenopedia and Genopedia: disease-centered and gene-centered views of the evolving knowledge of human genetic associations. Bioinformatics. 2010;26:145&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2796820</ArticleId><ArticleId IdType="pubmed">19864262</ArticleId></ArticleIdList></Reference><Reference><Citation>Wishart DS, Feunang YD, Guo AC, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res 2018; 46: D1074.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5753335</ArticleId><ArticleId IdType="pubmed">29126136</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Zhang S, Li F, et al. Therapeutic target database 2020: enriched resource for facilitating research and early development of targeted therapeutics. Nucleic Acids Res. 2020;48:D1031&#x2013;D1041.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7145558</ArticleId><ArticleId IdType="pubmed">31691823</ArticleId></ArticleIdList></Reference><Reference><Citation>Sareen D, O&#x2019;Rourke JG, Meera P, et al. Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat expansion. Sci Transl Med 2013; 5: 208ra149.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4090945</ArticleId><ArticleId IdType="pubmed">24154603</ArticleId></ArticleIdList></Reference><Reference><Citation>Dangond F, Hwang D, Camelo S, et al. Molecular signature of late-stage human ALS revealed by expression profiling of postmortem spinal cord gray matter. Physiol Genomics. 2004;16:229&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pubmed">14645737</ArticleId></ArticleIdList></Reference><Reference><Citation>Durrenberger PF, Fernando FS, Magliozzi R, et al. Selection of novel reference genes for use in the human central nervous system: a BrainNet Europe Study. Acta Neuropathol (Berl) 2012;124:893&#x2013;903.</Citation><ArticleIdList><ArticleId IdType="pubmed">22864814</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, Narayan R, Corsello SM, et al. A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles. Cell. 2017;171(1437&#x2013;1452):e17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5990023</ArticleId><ArticleId IdType="pubmed">29195078</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamb J, Crawford ED, Peck D, et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science. 2006;313:1929&#x2013;1935.</Citation><ArticleIdList><ArticleId IdType="pubmed">17008526</ArticleId></ArticleIdList></Reference><Reference><Citation>Sirota M, Dudley JT, Kim J, et al. Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci Transl Med 2011; 3: 96ra77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3502016</ArticleId><ArticleId IdType="pubmed">21849665</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U A. 2005;102:15545&#x2013;15550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1239896</ArticleId><ArticleId IdType="pubmed">16199517</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson MJ, Legendre P. An empirical comparison of permutation methods for tests of partial regression coefficients in a linear model. J Stat Comput Simul. 1999;62:271&#x2013;303.</Citation></Reference><Reference><Citation>Hayes AF. Cautions in testing variance equality with randomization tests. J Stat Comput Simul. 1997;59:25&#x2013;31.</Citation></Reference><Reference><Citation>Kennedy PE. Randomization Tests in Econometrics. J Bus Econ Stat. 1995;13:85&#x2013;94.</Citation></Reference><Reference><Citation>Marozzi M. A bi-aspect nonparametric test for the two-sample location problem. Comput Stat Data Anal. 2004;44:639&#x2013;648.</Citation></Reference><Reference><Citation>Shipley B. A permutation procedure for testing the equality of pattern hypotheses across groups involving correlation or covariance matrices. Stat Comput. 2000;10:253&#x2013;257.</Citation></Reference><Reference><Citation>Wan Y, Cohen J, Guerra R. A permutation test for the robust sib-pair linkage method. Ann Hum Genet. 1997;61:77&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">9066930</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith EP. Randomization methods and the analysis of multivariate ecological data. Environmetrics. 1998;9:37&#x2013;51.</Citation></Reference><Reference><Citation>Bailer AJ. Testing variance equality with randmization tests. J Stat Comput Simul. 1989;31:1&#x2013;8.</Citation></Reference><Reference><Citation>An Almost Exact Solution for the Multivariate Behrens-Fisher Problem - Fortunato Pesarin - Google Libri, https://books.google.it/books?id=qoLFoQEACAAJ&amp;dq=An+Almost+Exact+Solution+for+the+Multivariate+Behrens-Fisher+Problem&amp;hl=it&amp;sa=X&amp;ved=2ahUKEwjPpbrQwPXqAhXE-qQKHcfVD5gQ6AEwAHoECAEQAQ (accessed 30 July 2020).</Citation></Reference><Reference><Citation>Iglewicz B, Hoaglin D. How to detect and handle outliers. ASQC Basic Ref Qual Control Stat Tech 16.</Citation></Reference><Reference><Citation>Menche J, Sharma A, Kitsak M, et al. Uncovering disease-disease relationships through the incomplete interactome. Science&#xa0;2015; 347(6224): 1257601.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4435741</ArticleId><ArticleId IdType="pubmed">25700523</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanehisa M, Sato Y, Kawashima M, et al. KEGG as a reference resource for gene and protein annotation. Nucleic Acids Res. 2016;44:D457&#x2013;D462.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4702792</ArticleId><ArticleId IdType="pubmed">26476454</ArticleId></ArticleIdList></Reference><Reference><Citation>Jassal B, Matthews L, Viteri G, et al. The reactome pathway knowledgebase. Nucleic Acids Res. 2020;48:D498&#x2013;D503.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7145712</ArticleId><ArticleId IdType="pubmed">31691815</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuleshov MV, Jones MR, Rouillard AD, et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 2016;44:W90&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4987924</ArticleId><ArticleId IdType="pubmed">27141961</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishizuka T, Sakamoto Y, Sakurai T, et al. Modafinil increases histamine release in the anterior hypothalamus of rats. Neurosci Lett. 2003;339:143&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pubmed">12614915</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishizuka T, Murotani T, Yamatodani A. Modanifil activates the histaminergic system through the orexinergic neurons. Neurosci Lett. 2010;483:193&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pubmed">20696213</ArticleId></ArticleIdList></Reference><Reference><Citation>Minzenberg MJ, Carter CS. Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2008;33:1477&#x2013;1502.</Citation><ArticleIdList><ArticleId IdType="pubmed">17712350</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishizuka T, Murakami M, Yamatodani A. Involvement of central histaminergic systems in modafinil-induced but not methylphenidate-induced increases in locomotor activity in rats. Eur J Pharmacol. 2008;578:209&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="pubmed">17920581</ArticleId></ArticleIdList></Reference><Reference><Citation>Avelar AJ, Cao J, Newman AH, et al. Atypical dopamine transporter inhibitors R-modafinil and JHW 007 differentially affect D2 autoreceptor neurotransmission and the firing rate of midbrain dopamine neurons. Neuropharmacology. 2017;123:410&#x2013;419.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5546153</ArticleId><ArticleId IdType="pubmed">28625719</ArticleId></ArticleIdList></Reference><Reference><Citation>Richelson E, Nelson A. Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther. 1984;230:94&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">6086881</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim HD. Evaluation of Histamine H1-, H2-, and H3-Receptor Ligands at the Human Histamine H4 Receptor: Identification of 4-Methylhistamine as the First Potent and Selective H4 Receptor Agonist. J Pharmacol Exp Ther. 2005;314:1310&#x2013;1321.</Citation><ArticleIdList><ArticleId IdType="pubmed">15947036</ArticleId></ArticleIdList></Reference><Reference><Citation>Gillman PK. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol. 2007;151:737&#x2013;748.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2014120</ArticleId><ArticleId IdType="pubmed">17471183</ArticleId></ArticleIdList></Reference><Reference><Citation>Nowak JZ, Arrang JM, Schwartz JC, et al. Interaction between mianserin, an antidepressant drug, and central H1- and H2-histamine-receptors: In vitro and in vivo studies and radioreceptor assay. Neuropharmacology. 1983;22:259&#x2013;266.</Citation><ArticleIdList><ArticleId IdType="pubmed">6302549</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatzopoulos AK. Disease Models &amp; Mechanisms in the Age of Big Data. Dis Model Mech 2019; 12(8): dmm041699</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6737960</ArticleId><ArticleId IdType="pubmed">31439575</ArticleId></ArticleIdList></Reference><Reference><Citation>Jian-Sheng Lin MJ Bernard Roussel, Alexandre Gaspar, Yan Zhao, Yiping Hou, Markus Schmidt, Anne Jouvet. The unfinished journey with modafinil and discovery of a novel population of modafinil-immunoreactive neurons. Sleep Med 2018; 49: 40&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">30172629</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerrard P, Malcolm R. Mechanisms of modafinil: A review of current research. Neuropsychiatr Dis Treat. 2007;3:349&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2654794</ArticleId><ArticleId IdType="pubmed">19300566</ArticleId></ArticleIdList></Reference><Reference><Citation>Zager A. Modulating the immune response with the wake-promoting drug modafinil: A potential therapeutic approach for inflammatory disorders. Brain Behav Immun. 2020;88:878&#x2013;886.</Citation><ArticleIdList><ArticleId IdType="pubmed">32311496</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashemian SM, Farhadi T. A review on modafinil: the characteristics, function, and use in critical care. J Drug Assess. 2020;9:82&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7170336</ArticleId><ArticleId IdType="pubmed">32341841</ArticleId></ArticleIdList></Reference><Reference><Citation>Urban AE, Cuba&#x142;a WJ. The role of eugeroics in the treatment of affective disorders. Psychiatr Pol. 2020;54:21&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">32447354</ArticleId></ArticleIdList></Reference><Reference><Citation>Brola W, Ziomek M. Czernicki J [Fatigue syndrome in chronic neurological disorders] Neurol Neurochir Pol. 2007;41:340&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pubmed">17874343</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoser B. Myotonic Dystrophy Type 2. In: Adam MP, Ardinger HH, Pagon RA, et al. (eds) GeneReviews&#xae;. Seattle (WA): University of Washington, Seattle, http://www.ncbi.nlm.nih.gov/books/NBK1466/ (2006, accessed 15 September 2020).</Citation></Reference><Reference><Citation>Gibbons C, Pagnini F, Friede T, et al. Treatment of fatigue in amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev 2018; 1: CD011005.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6494184</ArticleId><ArticleId IdType="pubmed">29293261</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu X, Ma Y, Harding EC, et al. Genetic lesioning of histamine neurons increases sleep-wake fragmentation and reveals their contribution to modafinil-induced wakefulness. Sleep 2019;42(5):zsz031.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6519916</ArticleId><ArticleId IdType="pubmed">30722053</ArticleId></ArticleIdList></Reference><Reference><Citation>Mereu M, Bonci A, Newman AH, et al. The neurobiology of modafinil as an enhancer of cognitive performance and a potential treatment for substance use disorders. Psychopharmacology (Berl) 2013;229:415&#x2013;434.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3800148</ArticleId><ArticleId IdType="pubmed">23934211</ArticleId></ArticleIdList></Reference><Reference><Citation>Urbano FJ. Leznik RRLE . Modafinil enhances thalamocortical activity by increasing neuronal electrotonic coupling. Proc Natl Acad Sci 2007; 104: 12554&#x2013;12559.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1925036</ArticleId><ArticleId IdType="pubmed">17640897</ArticleId></ArticleIdList></Reference><Reference><Citation>Miriam Punzi SLS Tommaso Gili, Laura Petrosini, Carlo Caltagirone, Gianfranco Spalletta. Modafinil-Induced Changes in Functional Connectivity in the Cortex and Cerebellum of Healthy Elderly Subjects. Front Aging Neurosci&#xa0;2017; 30(9): 85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5371677</ArticleId><ArticleId IdType="pubmed">28424611</ArticleId></ArticleIdList></Reference><Reference><Citation>Yates CC, Charlesworth A, Reese NB, et al. Modafinil normalized hyperreflexia after spinal transection in adult rats. Spinal Cord. 2009;47:481&#x2013;485.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2726738</ArticleId><ArticleId IdType="pubmed">19079357</ArticleId></ArticleIdList></Reference><Reference><Citation>Gellersen HM, Guo CC, O&#x2019;Callaghan C, et al. Cerebellar atrophy in neurodegeneration-a meta-analysis. J Neurol Neurosurg Psychiatry. 2017;88:780&#x2013;788.</Citation><ArticleIdList><ArticleId IdType="pubmed">28501823</ArticleId></ArticleIdList></Reference><Reference><Citation>Sicong Tu, Ricarda&#xa0;MRT,&#xa0;Menke AL, et al. Regional thalamic MRI as a marker of widespread cortical pathology and progressive frontotemporal involvement in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2018; jnnp-2018&#x2013;318625.</Citation><ArticleIdList><ArticleId IdType="pubmed">30049750</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishizuka T, Murotani T, Yamatodani A. Action of modafinil through histaminergic and orexinergic neurons. Vitam Horm. 2012;89:259&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pubmed">22640618</ArticleId></ArticleIdList></Reference><Reference><Citation>Philipp O. Valko TES Yury V Gavrilov, Mihoko Yamamoto, Hasini Reddy, Johannes Haybaeck, Emmanuel Mignot, Christian R Baumann. Increase of histaminergic tuberomammillary neurons in narcolepsy. Ann Neurol 2013; 74: 794&#x2013;804.</Citation><ArticleIdList><ArticleId IdType="pubmed">24006291</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney ME, Pu H, Chiu AY, et al. Motor neuron degeneration in mice that express a human Cu,ZN superoxide dismutase mutation. Science. 1994;264:1772&#x2013;1775.</Citation><ArticleIdList><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Apolloni S, Amadio S, Fabbrizio P, et al. Histaminergic transmission slows progression of amyotrophic lateral sclerosis. J Chachexia Sarcopenia Muscle 2019; 10(4): 872&#x2013;893.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6711424</ArticleId><ArticleId IdType="pubmed">31020811</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu W, Chen Z. The roles of histamine and its receptor ligands in central nervous system disorders: An update. Pharmacology and Therapeutics 2017;175:116&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">28223162</ArticleId></ArticleIdList></Reference><Reference><Citation>Volont&#xe9; C, Morello G, Spampinato AG, et al. Omics-based exploration and functional validation of neurotrophic factors and histamine as therapeutic targets in ALS. Ageing Res Rev. 2020;62:101121.</Citation><ArticleIdList><ArticleId IdType="pubmed">32653439</ArticleId></ArticleIdList></Reference><Reference><Citation>Volont&#xe9; C, Apolloni S, Sabatelli M. Histamine beyond its effects on allergy: Potential therapeutic benefits for the treatment of Amyotrophic Lateral Sclerosis (ALS) Pharmacol Ther. 2019;202:120&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pubmed">31233766</ArticleId></ArticleIdList></Reference><Reference><Citation>Mora JS, Genge A, Chio A, et al. Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial. Amyotroph Lateral Scler Front Degener. 2020;21:5&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">31280619</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HY, Moon C, Kim KS, et al. Recombinant human erythropoietin in amyotrophic lateral sclerosis: a pilot study of safety and feasibility. J Clin Neurol Seoul Korea. 2014;10:342&#x2013;347.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4198716</ArticleId><ArticleId IdType="pubmed">25324884</ArticleId></ArticleIdList></Reference><Reference><Citation>Bedlack R. ALSUntangled 48: Perampanel (Fycompa) Amyotroph Lateral Scler Front Degener. 2019;20:453&#x2013;456.</Citation><ArticleIdList><ArticleId IdType="pubmed">30786786</ArticleId></ArticleIdList></Reference><Reference><Citation>Apolloni S, Fabbrizio P, Amadio S, et al. Actions of the antihistaminergic clemastine on presymptomatic SOD1-G93A mice ameliorate ALS disease progression. J Neuroinflammation. 2016;13:191.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4994328</ArticleId><ArticleId IdType="pubmed">27549088</ArticleId></ArticleIdList></Reference><Reference><Citation>Apolloni S, Fabbrizio P, Parisi C, et al. Clemastine Confers Neuroprotection and Induces an Anti-Inflammatory Phenotype in SOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis. Mol Neurobiol. 2016;53:518&#x2013;531.</Citation><ArticleIdList><ArticleId IdType="pubmed">25482048</ArticleId></ArticleIdList></Reference><Reference><Citation>Michael J, Minzenberg CSC. Modafinil: A Review of Neurochemical Actions and Effects on Cognition. Neuropsychopharmacology. 2007;33:1477&#x2013;1502.</Citation><ArticleIdList><ArticleId IdType="pubmed">17712350</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>